Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc(INBS)の株式分析

$1.990

+0.260 (+13.07%)終値時点

Loading chart…
高値
2.000
始値
1.750
出来高加重平均価格
1.90
出来高
73.60K
時価総額
5.83M
安値
1.720
売買代金
140.09K
EV/EBITDA(TTM)
-0.15

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.

ibs.inc

AI分析 of Intelligent Bio Solutions Inc (INBS)

買い

Intelligent Bio Solutions Inc is a good buy right now due to its recent price increase of 13.07% over the last five days, indicating strong momentum. The RSI is at 74.51, suggesting it is overbought, but the stock has shown a significant recovery from its 52-week low of 1.35, currently trading at 1.99. The company has also secured FDA submission for its drug screening system, which could tap into a multi-billion-dollar market, providing a strong growth catalyst. However, the main risk is its high net loss of 3.91 million in Q4 2026, which could impact future profitability.

バリュエーション指標

Intelligent Bio Solutions Inc(INBS)の現在の予想PERは0.00で、5年平均は-1.23です。

予想PER

適正
5年平均 P/E
-1.23
現在のP/E
0.00
割高
0.99
割安
-3.45

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
-0.01
現在のEV/EBITDA
-0.15
割高
0.03
割安
-0.04

予想PSR

適正
5年平均 P/S
9.23
現在のP/S
0.74
割高
35.98
割安
-17.51

Alphio AI による INBS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%INBS

$2.95

シナリオ価格

基

基本

基本 · 50%INBS

$2.44

シナリオ価格

弱

弱気

弱気 · 25%INBS

$1.86

シナリオ価格

イベントタイムライン

2026-09-09 (ET)

09:00:00

Intelligent Bio Solutions Submits Drug Screening System to FDA

2026-09-01 (ET)

09:00:00

Intelligent Bio Solutions Enters Agreement to Issue 2,036,659 Shares

2026-08-11 (ET)

09:30:00

Intelligent Bio Solutions Completes Drug Screening Study

2026-07-21 (ET)

09:00:00

Intelligent Bio Solutions Completes Precision Testing

2026-06-02 (ET)

09:10:00

Intelligent Bio Solutions Initiates Multi-Site Study for FDA Submission

ニュース

INBS のよくある質問 — Alphio AI が回答

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Intelligent Bio Solutions Inc is a good buy right now due to its recent price increase of 13.07% over the last five days, indicating strong momentum. The RSI is at 74.51, suggesting it is overbought, but the stock has shown a significant recovery from its 52-week low of 1.35, currently trading at 1.99. The company has also secured FDA submission for its drug screening system, which could tap into a multi-billion-dollar market, providing a strong growth catalyst. However, the main risk is its high net loss of 3.91 million in Q4 2026, which could impact future profitability.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める